Clinical Trials in Genitourinary Cancers: KEYLYNK-010, KEYNOTE-866, and PDIGREE

May 5, 2020
Brielle Gregory, ASCO staff

Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.

In this podcast, Brian Shuch, MD, leads a discussion with Neeraj Agarwal, MD; Petros Grivas, MD, PhD; and Sumanta (Monty) Pal, MD, about 3 clinical trials in prostate, bladder, and kidney cancer.

  • The KEYLYNK-010 phase III clinical trial is testing whether using a combination of 2 immunotherapy drugs can help people with metastatic castration-resistant prostate cancer live longer and whether it keeps the cancer from growing or spreading, called progression, for a longer duration. [7:08]

  • The KEYNOTE-866 phase III clinical trial aims to answer whether treating people with muscle-invasive bladder cancer using immunotherapy plus chemotherapy before bladder-removal surgery lessens the chance of cancer coming back, called a recurrence, and helps patients live longer. [14:18]

  • The PDIGREE phase III clinical trial is studying whether treating people who have poor-risk or intermediate-risk advanced kidney cancer with a combination of targeted therapy and immunotherapy after 3 months of initial immunotherapy treatment delays cancer recurrence and progression. [20:01]

Dr. Shuch is the director of the Kidney Cancer Program at UCLA Health, the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at the institution, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Pal is co-director of City of Hope's Kidney Cancer Program, the head of the kidney and bladder cancer disease team at the institution, and the Cancer.Net Associate Editor for Genitourinary Cancers. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers.

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.